PHAR
NASDAQPharming Group N.V. ADS each representing 10
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$9.66-4.61 (-32.27%)
2026-07-162026-10-16
News · 26 weeks27-43%
2026-04-262026-10-18
Mix1690d
- SEC Filings7(44%)
- Other7(44%)
- Earnings1(6%)
- Leadership1(6%)
Latest news
25 items- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markersAll participants who completed the study elected to continue receiving treatment in a long-term extension study Leiden, the Netherlands, October 14, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its Phase II trial of leniol
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces CEO transitionLeiden, the Netherlands, September 29, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect. To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board has started a formal searc
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSIf approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or moreDecision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kgPDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and olde
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026 Leiden, the Netherlands, September 22, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been accepted at the 22nd Biennial Meeting
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be available in October Leiden, the Netherlands, September 11, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years weighing at leas
- PRPharming Group to participate in September investor conferencesLeiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of September: H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the "Events and presentations" and "Our news" sections of Pharming’s website. Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026 For more information about these conferences, or to schedule
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderLaunch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan Leiden, the Netherlands, August 13, 2026: Pharming Group (NASDAQ:PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older, following its inclusion on the Japan National Health Insurance (NHI) drug price list. With this launch, Japan is now the first market where Joenja is commercially available for children aged 4 to 11. "This launch is an important milest
- PRPharming Group to participate in Canaccord Genuity 46th Annual Growth ConferenceLeiden, the Netherlands, August 4, 2026: Pharming Group N.V. (NASDAQ:PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP Investor Relations and Capital Markets, will participate in a Fireside Chat Q&A session on Wednesday, August 12 at 10:00 EDT/16:00 CEST. For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Canaccord Genuity representative. About Pharming Group N.V.Pharming Group N.V. (NASDAQ:PHAR) is a global biopharmaceutical company dedicated to tr
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic useFor investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the second quarter 2025 and a 24% increase compared to the first quarter 2026, with active patient base 93% of year-ago and strong new patient enrollmentsJoenja® revenue was US$17.9 million, a 40% increase compared to the second quarter 2025, reflecting continued strong U.S. and international growth, with first European launch in Germany after quarter-endSecond quarter operating profit amounted to US$1.3 million compared to US$10.8 million in the second quarter 2025, impacted by manuf
- PRPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and provide a business update on Thursday, July 30, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BId285845cff504c39931913d279f646ea Once registered, dial-in information and a unique PIN will be provided, allowi
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSIf approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosingSeparate sNDA for lower weight pediatric patients planned for second half 2026 Leiden, the Netherlands, June 4, 2026: Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhi
- PRPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkLeiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (NASDAQ:PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, 2026. Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Thursday, June 4 at 11:05am EDT/17:05 CEST. A live webcast and replay of the presentation will be made available in the "Events and presentations" and "Our news" sections of Pharming's website. For more information about the conference, or to schedule a one-on-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at investor@pharming.com or your Jefferies repres
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PREuropean Commission grants marketing authorization to Pharming's Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionJoenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12 years and olderFirst European launch expected in Germany in Q3 2026Approval adds to Joenja® approvals in the United States, United Kingdom, Japan, Australia and Israel, supporting Pharming's global expansion strategy Leiden, the Netherlands, May 22, 2026: Pharming Group ("Pharming" or "the Company") (NASDAQ:PHAR) today announced that the European Commission (EC) has granted marketing authorization for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
PHAR FAQ
6 questionsWhat does Pharming Group N.V. ADS each representing 10 do?
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase...Where does PHAR stock trade?
Pharming Group N.V. ADS each representing 10 (PHAR) is listed on NASDAQ.What sector and industry is PHAR in?
Pharming Group N.V. ADS each representing 10 operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PHAR?
Pharming Group N.V. ADS each representing 10 has had 2 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $3700.00 price target on 2026-04-10. Recent price targets range from $1400.00 to $3700.00.What companies are similar to PHAR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PHAR side-by-side with any of them on Quantisnow.How can I track PHAR on Quantisnow?
Quantisnow aggregates Pharming Group N.V. ADS each representing 10's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHAR to receive live email and push alerts on every new disclosure.